ATRS stock forecast
Our latest prediction for Antares Pharma, Inc.'s stock price was made on the Aug. 21, 2018 when the stock price was at 3.65$.
In the short term (2weeks), ATRS's stock price should outperform the market by 1.03%. During that period the price should oscillate between -7.25% and +10.34%.
In the medium term (3months), ATRS's stock price should outperform the market by 6.99%. During that period the price should oscillate between -14.93% and +27.43%.Get email alerts
Create a solid portfolio with ATRS
About Antares Pharma, Inc.
Antares Pharma, Inc. is a combination drug device company, which engages in the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its proprietary products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ.
At the moment the company generates 59M USD in revenues.
On its last earning announcement, the company reported a loss of -0.11$ per share.
The book value per share is 0.16$
Three months stock forecastAug. 21, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|